Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LFF571 in moderate Clostridium difficile infections
NCT01232595Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2010
- Primary completion
- Jul 2013
- Modality
- Antimicrobial Peptides, Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of LFF-571 in Clostridioides difficile infection (CDI), sponsored by Novartis. Started Oct 2010; status: completed.
02
Drugs
LFF-571
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT01232595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01232595.